Pioglitazone is a substrate of CYP2C8, CYP2C9 and CYP3A4, but is not an inducer of them or CYP1A. Pioglitazone does not inhibit CYP2C8 or CYP3A4.

Pyridyl ethoxybenzyl thiazolidindione

Common side effects are back pain and upper respiratory tract infections.

Irrelevant

Pioglitazone is listed to be metabolized by CYP2C8, CYP2C9 and CYP3A4 (Kajosaari 2006, Norsk legemiddelhåndbok, Scheen 2007). The elimination half-life is 5-6 hours. Clinical studies showed no induction of CYP1A, CYP2C8, CYP2C9 (SPC) or CYP3A4 (Nowak 2002, Scheen 2007, SPC). Pioglitazone inhibits CYP2C8 and CYP3A4 (Kajosaari 2006, Scheen 2007), and has also been shown to be a mechanism-based inhibitor of CYP3A4 in vitro (Lim 2005, Sinz 2006). In vivo studies have however, shown that pioglitazone does not increase the plasma concentration of repaglinide, a CYP2C8 and CYP3A4 substrate, which indicates that pioglitazone does not significantly inhibit these enzymes (Kajosaari 2006, Scheen 2007).